Integrated Precision Framework for Managing Inflammatory–Metabolic Multimorbidity in Contemporary Internal Medicine
DOI:
https://doi.org/10.64784/144Keywords:
Complex multimorbidity, precision medicine, internal medicine, dermatology-endocrinology interface, cardiometabolic clustering, polypharmacy, guideline conflict, cardiovascular risk stratification, predictive modeling, patient-centered careAbstract
Complex multimorbidity has become a defining feature of contemporary internal medicine, particularly within inflammatory–metabolic intersections such as dermatologic and endocrine disorders. As chronic conditions cluster in structured cardiometabolic networks, traditional disease-specific guideline approaches increasingly generate therapeutic conflict, polypharmacy, and reduced predictive accuracy in high-complexity patients. This study developed and evaluated an integrated precision decision-making framework designed to reconcile inflammatory burden, endocrine dysregulation, cardiovascular risk stratification, medication safety, and patient-centered prioritization within a unified clinical model. Multidimensional analysis demonstrated coherent cardiometabolic clustering with measurable inflammatory–metabolic overlap. As multimorbidity complexity increased, medication burden, adverse drug event risk, and guideline conflict rose progressively under traditional management approaches, while predictive discrimination declined. In contrast, the integrated precision framework showed lower conflict indices and improved predictive performance across escalating strata of complexity. Outcome prioritization analysis revealed a structured distribution balancing cardiovascular stabilization, metabolic control, inflammatory skin management, polypharmacy reduction, and quality-of-life considerations. These findings support the transition from fragmented, disease-centered optimization toward an integrated, value-based, and precision-guided model of internal medicine capable of addressing the biological and therapeutic interdependence characteristic of complex chronic disease networks.
References
[1] M. Barnett et al., “Epidemiology of multimorbidity and implications for health care, research, and medical education,” Lancet, vol. 380, no. 9836, pp. 37–43, 2012, doi: 10.1016/S0140-6736(12)60240-2.
[2] K. E. Fortin et al., “Multimorbidity’s many challenges,” BMJ, vol. 334, no. 7602, pp. 1016–1017, 2007, doi: 10.1136/bmj.39201.463819.2C.
[3] World Health Organization, “Multimorbidity: Technical series on safer primary care,” WHO, 2016, doi: 10.2471/BLT.16.180893.
[4] M. E. Porter and E. O. Teisberg, “Redefining health care: Creating value-based competition,” Harvard Business Review, vol. 84, no. 6, pp. 65–76, 2006, doi: 10.1056/NEJMp1310415.
[5] J. A. Tinetti, C. M. Bogardus, and J. V. Agostini, “Potential pitfalls of disease-specific guidelines for patients with multiple conditions,” N. Engl. J. Med., vol. 351, no. 27, pp. 2870–2874, 2004, doi: 10.1056/NEJMsb042458.
[6] C. Boyd et al., “Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases,” JAMA, vol. 294, no. 6, pp. 716–724, 2005, doi: 10.1001/jama.294.6.716.
[7] R. L. Boyd and A. Darer, “The impact of multimorbidity on health outcomes,” J. Gen. Intern. Med., vol. 25, no. 1, pp. 8–12, 2010, doi: 10.1007/s11606-009-1177-8.
[8] E. A. Bayliss et al., “Understanding the context of health for patients with multiple chronic conditions,” Ann. Fam. Med., vol. 5, no. 5, pp. 395–402, 2007, doi: 10.1370/afm.769.
[9] J. B. Salisbury, “Multimorbidity: Redesigning health care for people who use it,” Lancet, vol. 386, no. 9999, pp. 1784–1786, 2015, doi: 10.1016/S0140-6736(15)60672-9.
[10] E. Topol, “High-performance medicine: The convergence of human and artificial intelligence,” Nat. Med., vol. 25, no. 1, pp. 44–56, 2019, doi: 10.1038/s41591-018-0300-7.
[11] A. Ashley, “Towards precision medicine,” Nat. Rev. Genet., vol. 17, no. 9, pp. 507–522, 2016, doi: 10.1038/nrg.2016.86.
[12] F. S. Collins and H. Varmus, “A new initiative on precision medicine,” N. Engl. J. Med., vol. 372, no. 9, pp. 793–795, 2015, doi: 10.1056/NEJMp1500523.
[13] R. B. D’Agostino et al., “General cardiovascular risk profile for use in primary care,” Circulation, vol. 117, no. 6, pp. 743–753, 2008, doi: 10.1161/CIRCULATIONAHA.107.699579.
[14] G. S. Krumholz, “Big data and new knowledge in medicine,” Circulation, vol. 130, no. 17, pp. 1517–1518, 2014, doi: 10.1161/CIRCULATIONAHA.114.010504.
[15] J. B. S. Holmes et al., “Polypharmacy and adverse drug events in older adults,” BMJ, vol. 350, h1059, 2015, doi: 10.1136/bmj.h1059.
[16] T. Fried et al., “Health outcome prioritization in multimorbidity,” J. Gen. Intern. Med., vol. 26, no. 12, pp. 1533–1538, 2011, doi: 10.1007/s11606-011-1880-1.
[17] M. J. Field and K. Lohr, Clinical Practice Guidelines: Directions for a New Program, Washington, DC: National Academy Press, 1990, doi: 10.17226/1626.
[18] A. A. Gawande, “The checklist manifesto and medical complexity,” N. Engl. J. Med., vol. 360, no. 5, pp. 491–493, 2009, doi: 10.1056/NEJMp0806786.
[19] S. T. Weissman et al., “Risk stratification in hospitalized medical patients,” JAMA Intern. Med., vol. 174, no. 4, pp. 613–620, 2014, doi: 10.1001/jamainternmed.2014.152.
[20] A. Banerjee et al., “Machine learning and multimorbidity prediction models,” Lancet Digit. Health, vol. 3, no. 6, pp. e323–e334, 2021, doi: 10.1016/S2589-7500(21)00067-9.
